Viking Therapeutics (VKTX) stock ripped higher on Tuesday morning after the biopharmaceutical company published promising clinical trial data.
Investors rallied around new Phase 2 top-line results for the firm’s flagship weight-loss candidate, VK2735, which showed patients can trim dosing frequency without sacrificing significant weight loss progress.
Note that Viking Therapeutics shares have been a volatile investment in 2026, now up nearly 10% versus their price at the start of this year, but down some 7% versus their July high.
What we know about Viking Therapeutics’ Phase 2 update
After an initial 21-week induction period where patients achieved between 16% and 19% weight reduction, Viking transitioned participants of its Phase 2 clinical trial to less frequent maintenance schedules.
Patients switched to an “every-other-week” regimen retained up to 97% of their initial weight loss over 12 weeks, while those placed on monthly dosing retained up to 90%.
Plus, an exploratory cohort continuing weekly 17.5 mg injections reached 22% placebo-adjusted weight loss by Week 33 without hitting a plateau.
VKTX shares are rallying because these results address one of the steepest operational bottlenecks in the anti-obesity drug landscape: patient adherence and treatment fatigue under weekly injection schedules.
Beyond demonstrating efficacy, VK2735 delivered a clean safety profile with gastrointestinal side effects comparable to placebo during maintenance, reinforcing its potential to rival “established” blockbusters like Lilly’s Zepbound and Novo’s Wegovy.
Is it already too late to invest in VKTX shares?
While the headline initially triggered aggressive buying, holding onto these substantial gains over the medium term depends on clinical execution and commercial strategy.
Clinical-stage biotechs frequently experience profit-taking selloffs following major trial readouts as momentum traders exit positions.
However, Viking Therapeutics stock has multiple “structural catalysts” that could help consolidate these gains.
Unlike single-shot clinical plays, the company is advancing both subcutaneous and oral iterations of VK2735, with Phase 3 VANQUISH trials already fully enrolled and an oral Phase 3 expected to initiate before year-end 2026.
If VKTX can successfully execute “Part 2” of its current study – testing oral maintenance options following injectable induction – it will establish a unique “shot-to-pill” treatment ladder that few competitors can replicate.
What to expect from Viking Therapeutics’ stock
Looking ahead, the long-term thesis for VKTX stock is rooted in whether the company intends to commercialize VK2735 independently or position itself for an acquisition by a big pharmaceutical conglomerate.
Navigating global supply chains and scaling production of GLP-1/GIP therapies requires billions in capital – a challenge that could strain Viking’s balance sheet as Phase 3 studies progress toward commercial filing.
Big pharma players seeking entry or expanded market share in the massive metabolic space view flexible-dosing assets as prime acquisition targets.
But if Viking decides to go at it alone, cash burn rates and future equity dilution remain legitimate risk factors for share retention.
That said, with promising clinical data backing its pipeline and a distinct competitive advantage in maintenance convenience, the biotech has firmly positioned itself as a pivotal force in the evolving obesity market.
The post Can Viking Therapeutics stock retain today’s gains? appeared first on Invezz
